In gliomas, ARID1A mutations in WHO grade 3 oligodendrocyte tumors are linked to poorer progression‐free survival,18 yet the role of ARID1A in GBM remains to be fully unraveled. This evidence concerns the gene ARID1A and central nervous system cancer.